Elanco General Counsel Michael-Bryant Hicks to Depart After Successful Company Stand-Up and Acquisition Completion

Rhea-AI Summary

Elanco Animal Health (NYSE: ELAN) announced the departure of executive vice president Michael-Bryant Hicks on March 2. Hicks played a crucial role since 2018 in guiding the company through its IPO and the acquisition of Bayer Animal Health. CEO Jeff Simmons expressed gratitude for Hicks' contributions, emphasizing his unique skill set in transforming Elanco into a standalone entity. Hicks plans to leverage his experience in future leadership roles. The company is currently in the process of finding a replacement for Hicks.

Positive

• Hicks contributed significantly to the successful acquisition of Bayer Animal Health.
• His expertise helped Elanco transition into a standalone animal health company.

Negative

• The departure of a high-level executive may create uncertainty during the transition period.

Elanco Animal Health Incorporated (NYSE: ELAN) today announced the departure of executive vice president Michael-Bryant Hicks (“Hicks”). He joined Elanco in 2018 as General Counsel and Corporate Secretary to prepare the company for IPO, build the Legal department structure for the stand-alone company, and complete the successful acquisition of Bayer Animal Health.

“I am grateful to Hicks for his contributions to Elanco, providing the legal expertise we needed to successfully transform into a stand-alone animal health company while completing the industry’s biggest acquisition,” said Jeff Simmons, president and CEO at Elanco. “His skill set is unique, and I fully support his aspiration to lead other companies through the same type of dynamic transformation Elanco’s undertaken.”

Hicks will depart Elanco on March 2 and the process to backfill the role is currently underway.

“The last three years at Elanco have been some of the most rewarding in my career, with the opportunity to work alongside talented teammates and make significant contributions in the company’s formative years,” said Michael-Bryant Hicks. “I’m looking forward to taking this experience forward to help others navigate these same types of exciting opportunities.”

ABOUT ELANCO

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability/ESG Pledges – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005106/en/

FAQ

What led to Michael-Bryant Hicks' departure from Elanco?

Hicks is leaving to pursue leadership opportunities after playing a key role in Elanco's transformation.

When is Michael-Bryant Hicks leaving Elanco?

Hicks will leave the company on March 2.

How did Hicks impact Elanco's acquisition of Bayer Animal Health?

Hicks provided essential legal support that facilitated the successful acquisition.

What role did Hicks hold at Elanco?

Hicks served as executive vice president, General Counsel, and Corporate Secretary.

What is Elanco's focus in the animal health sector?

Elanco is dedicated to delivering innovative solutions for preventing and treating diseases in farm animals and pets.